TRML Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 39.21%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.16%. Given that Gilead Sciences, Inc. has higher upside potential than Tourmaline Bio, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Tourmaline Bio, Inc..

Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.79 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 5.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inhibrx Biosciences, Inc. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of -2204.15%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Inhibrx Biosciences, Inc.'s return on equity of -151.49%.

Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Inhibrx Biosciences, Inc. has an analysts' consensus of $12.00 which suggests that it could fall by -85.04%. Given that Tourmaline Bio, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Tourmaline Bio, Inc. is more attractive than Inhibrx Biosciences, Inc..

Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inhibrx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inhibrx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Inhibrx Biosciences, Inc. pays out -- of its earnings as a dividend.

Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Inhibrx Biosciences, Inc. quarterly revenues of --. Tourmaline Bio, Inc.'s net income of -$23.1M is higher than Inhibrx Biosciences, Inc.'s net income of -$35.3M. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Inhibrx Biosciences, Inc.'s PE ratio is 0.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 872.14x for Inhibrx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 31.72%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Eli Lilly & Co.'s return on equity of 106.26%.

Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Eli Lilly & Co. has higher upside potential than Tourmaline Bio, Inc., analysts believe Eli Lilly & Co. is more attractive than Tourmaline Bio, Inc..

Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia Corp. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of -6.5%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Liquidia Corp.'s return on equity of -221.75%.

Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Liquidia Corp. has an analysts' consensus of $44.00 which suggests that it could grow by 27.87%. Given that Liquidia Corp. has higher upside potential than Tourmaline Bio, Inc., analysts believe Liquidia Corp. is more attractive than Tourmaline Bio, Inc..

Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.777%.

Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.

Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Liquidia Corp. quarterly revenues of $54.3M. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Liquidia Corp.'s net income of -$3.5M. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 42.48x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.